-
Open Access Surgery
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Xenon-based anesthesia: theory and practice
Review
(3793) Views (1360) Full article downloads
Authors: Jan-Hinrich Baumert
Published Date August 2009
Volume 2009:2 Pages 5 - 13
DOI: http://dx.doi.org/10.2147/OAS.S4592
Jan-Hinrich Baumert
Dept of Anaesthesiology, UMC St Radboud, Nijmegen, Netherlands
Abstract: Xenon has been in use as an anesthetic for more than 50 years. Although it exhibits some of the properties of an ideal anesthetic, the technical complexity of xenon equipment and the high cost of the gas have prevented widespread use of xenon anesthesia. The main beneficial features of xenon anesthesia are fast induction and emergence because of low solubility in blood and tissues, along with remarkably stable hemodynamics even in patients with impaired cardiac function. Xenon has proven to be a safe and well-tolerated anesthetic in clinical trials. The primary mechanism by which xenon produces anesthesia – antagonism at the neuronal N-methyl-D-aspartate receptor – and the absence of vasodilating effects distinguish xenon from most other inhaled and intravenous anesthetics. In addition, xenon can protect cells from ischemia-reperfusion damage. This effect was demonstrated in myocardium and neuronal cells as well. Myocardial and cerebral infarction sizes after ischemia can be reduced substantially by xenon, even when administered after the initial insult. Because of its high cost, routine xenon anesthesia may be justified only if it is associated with fewer perioperative complications, shorter duration of hospital stay or significant reduction of perioperative risk. Clinical studies to identify a specific group of patients in which these requirements are met are still lacking.
Keywords: xenon, anesthesia
Readers of this article also read:
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections
Anidulafungin and its role in candida infections
Topical thrombin preparations and their use in cardiac surgery
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Distal femoral opening-wedge osteotomy for lateral compartment osteoarthritis of the knee
- Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
- Neurotransmitter testing of the urine: a comprehensive analysis
- Ipsilateral pedicle screw placement with contralateral percutaneous facet screws: Early results with an alternative in lumbar arthrodesis




